Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) had its price target reduced by analysts at Stifel Nicolaus from $176.00 to $142.00 in a research report released Friday to clients and investors, Fly reports. Stifel Nicolaus’ price target would suggest a potential upside of 138.02% from the company’s current price.
RARE has been the subject of a number of other research reports. Goldman Sachs Group cut its price target on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating on the stock in a Tuesday, May 24 research report. Cowen lowered his price target on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 research note. StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a Tuesday, June 21 research report. Piper Sandler lowered her price target on Ultragenyx Pharmaceutical from $170.00 to $135.00 and set an “overweight” rating for the company in a Wednesday, May 18 research report. Finally, Credit Suisse Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “outperforming” rating and raised its price target for the stock from $99.00 to $105.00 in a Wednesday, March 16 report. . Two investment analysts have assigned the stock a sell rating, three have issued a hold rating and seven have assigned the company’s stock a buy rating. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $109.75.
Ultragenyx Pharmaceutical stock opened at $59.66 on Friday. The company has a market capitalization of $4.17 billion, a PE ratio of -8.68 and a beta of 1.61. The company’s 50-day moving average is $55.87 and its two-hundred-day moving average is $67.38. Ultragenyx Pharmaceutical has a 1 year low of $45.20 and a 1 year high of $104.38.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last released its quarterly results on Thursday, May 5. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.76) by ($0.43). Ultragenyx Pharmaceutical posted a negative return on equity of 49.18% and a negative net margin of 141.65%. The company posted revenue of $79.94 million for the quarter, versus a consensus estimate of $84.25 million. In the same period of the previous year, the company had earned earnings per share of ($2.03). Ultragenyx Pharmaceutical revenue decreased 19.6% compared to the same quarter last year. On average, research analysts expect Ultranyx Pharmaceutical to post earnings per share of -7.15 for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of RARE. IndexIQ Advisors LLC bought a new position in shares of Ultragenyx Pharmaceutical in Q1 worth $44,000. Lazard Asset Management LLC increased its stake in Ultragenyx Pharmaceutical shares by 36.6% in Q1. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company valued at $64,000 after buying an additional 240 shares last quarter. Alpha Paradigm Partners LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter for a value of approximately $113,000. Harbor Capital Advisors Inc. acquired a new stake in Ultragenyx Pharmaceutical during Q1 valued at approximately $169,000. Finally, Essex Investment Management Co. LLC increased its position in Ultragenyx Pharmaceutical by 14.9% in the 1st quarter. Essex Investment Management Co. LLC now owns 2,682 shares of the biopharmaceutical company worth $195,000 after buying 348 additional shares in the last quarter. 97.49% of the shares are held by institutional investors.
Ultragenyx Pharmaceutical Company Profile (Get a rating)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Ultragenyx Pharmaceutical right now?
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here